1-20 of 546 results for subject:Screening
Librarians' tools
- Search time
- 0.301 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
Month
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of the introduction of HPV primary screening in Northern Ireland.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of the introduction of HPV primary screening in Northern Ireland.
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Northern Ireland Department of Health, Social Services and Public Safety on the introduction of HPV primary screening in Northern Ireland.
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Northern Ireland Department of Health, Social Services and Public Safety on the introduction of HPV primary screening in Northern Ireland.
To ask the Secretary of State for Health and Social Care, what the average waiting time for cervical screening results was in each region; and what assessment he has made of trends in the length of waiting times as a result of HPV screening in each of the last three...
To ask the Secretary of State for Health and Social Care, what the average waiting time for cervical screening results was in each region; and what assessment he has made of trends in the length of waiting times as a result of HPV screening in each of the last three...
It has not proved possible to respond to the hon. Member in the time available before Dissolution.
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement on the Publication of Professor Sir Mike Richards’ Review of National Adult Screening Programmes, Official Report, HCWS11, when sole responsibility for the delivery of adult screening programmes will be transferred to NHS England.
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement on the Publication of Professor Sir Mike Richards’ Review of National Adult Screening Programmes, Official Report, HCWS11, when sole responsibility for the delivery of adult screening programmes will be transferred to NHS England.
We are currently reviewing the recommendations made in Professor Sir Mike Richards’ report and are working closely with NHS England and NHS Improvement, Public Health England and other partners across the health system to develop an implementation plan, which we expect to publish early next year. This will ensure that any proposed changes can be implemented smoothly and without compromising the safety and efficacy of our current screening programmes.
To ask the Secretary of State for Health and Social Care, with reference to his Written Statement of 16 September 2019, Official Report, HCWS11, what the timeframe is for NHSX to complete its delivery of new IT systems to support the breast screening programme.
To ask the Secretary of State for Health and Social Care, with reference to his Written Statement of 16 September 2019, Official Report, HCWS11, what the timeframe is for NHSX to complete its delivery of new IT systems to support the breast screening programme.
NHSX, Public Health England, NHS Digital, NHS England and NHS Improvement have established a programme to modernise the IT systems on which the national screening programmes are delivered. The programme is applying the Government Digital Service’s ‘agile’ approach and has recently commenced a prototyping ('alpha') phase focussed on the “call and recall” of screening participants. The alpha will end in January 2020, at which point it will be clearer what is required and the likely timescales.
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement of 16 October 2019, Publication of Professor Sir Mike Richards’ Review of National Adult Screening Programmes, HCWS 11, when his Department plans to publish the implementation plan relating to Professor Sir Mike Richards’...
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement of 16 October 2019, Publication of Professor Sir Mike Richards’ Review of National Adult Screening Programmes, HCWS 11, when his Department plans to publish the implementation plan relating to Professor Sir Mike Richards’...
We are currently reviewing the recommendations made in Professor Sir Mike Richards’ report and are working closely with NHS England and NHS Improvement, Public Health England and other partners across the health system to develop an implementation plan, which we expect to publish early next year.
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement of 16 October 2019, Publication of Professor Sir Mike Richards’ Review of National Adult Screening Programmes, HCWS 11, which recommendations of Professor Sir Mike Richards’ Review of National Adult Screening Programmes he accepts...
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement of 16 October 2019, Publication of Professor Sir Mike Richards’ Review of National Adult Screening Programmes, HCWS 11, which recommendations of Professor Sir Mike Richards’ Review of National Adult Screening Programmes he accepts...
We are currently reviewing the recommendations made in Professor Sir Mike Richards’ report and are working closely with NHS England and NHS Improvement, Public Health England and other partners across the health system to develop an implementation plan, which we expect to publish early next year.
To ask the Secretary of State for Health and Social Care, what the role of the life sciences industry will be in delivering the Genomic Healthcare Strategy.
To ask the Secretary of State for Health and Social Care, what the role of the life sciences industry will be in delivering the Genomic Healthcare Strategy.
The life sciences sector is a crucial pillar of the United Kingdom economy, employing close to a quarter of a million people and providing almost £74 billion in turnover annually. As part of the Life Sciences Sector Deal 2, companies have already committed to co-funding a number of leading genomics initiatives, recognising the important role the sector plays in supporting the development of genomic healthcare.
Two landmark industry collaborations that will feature in the Genomic Healthcare Strategy include:
- Whole Genome Sequencing of the UK Biobank: this will be funded by contributions from the UK Government, the Wellcome Trust and industry partners, with Johnson and Johnson, Amgen, GlaxoSmithKline and AstraZeneca providing a combined £100 million to the project; and
- The Accelerating Detection of Disease Challenge: businesses and charities are expected to jointly invest up to £160 million, in addition to £79 million Government investment.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 October 2019 to Question 1906, what assessment his Department has made of the most appropriate test for patients presenting with symptoms of cervical cancer; and what steps his Department is taking to ensure...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 October 2019 to Question 1906, what assessment his Department has made of the most appropriate test for patients presenting with symptoms of cervical cancer; and what steps his Department is taking to ensure...
All general practitioners (GPs) should use the latest evidence-based guidance from the National Institute for Health and Care Excellence (NICE) to identify people at risk of cancer. The NICE referral guidelines for suspected gynaecological cancers recommend that GPs consider a suspected cancer pathway referral (for an appointment within two weeks) for women if, on examination, the appearance of their cervix is consistent with cervical cancer.
People of any age who present with symptoms of cervical cancer, should make an appointment with their GP, who may then make a cancer pathway referral to a gynaecologist for examination. This may result in an additional referral for symptomatic colposcopic examination if cancer is suspected.
To ask Her Majesty's Government what plans, if any, they have to establish mandatory annual health screenings.
To ask Her Majesty's Government what plans, if any, they have to establish mandatory annual health screenings.
The Department does not have any plans to establish mandatory annual health screenings. Screening in the United Kingdom is undertaken through informed consent.
There are 11 national screening programmes that are recommended by the UK National Screening Committee, which cover 37 conditions across adults and babies (antenatal and neonatal). Approximately 11 million people are invited to participate in screening programmes each year.
There is also the NHS Health Check service which is a health check-up for adults in England aged 40-74 every five years. It is designed to spot early signs of stroke, kidney disease, heart disease, type 2 diabetes or dementia. The Government’s recent Green Paper Advancing our health: prevention in the 2020s announced the intention to undertake a review of the NHS Health Checks programme to maximise the benefits it delivers in the next decade.
Professor Richards’ review of National Adult Screening programmes was published on 16 October and as part of this review it explored the future of screening. The Department, NHS England and Public Health England will consider the recommendations of Professor Richards’ report and publish an implementation plan in due course.
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of women attending breast and cervical cancer screening programmes.
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of women attending breast and cervical cancer screening programmes.
Prevention, public health and early diagnosis are key priorities for this Government, but we acknowledge that more can be done. The recently published Independent Review of Adult Screening Programmes, conducted by Professor Sir Mike Richards, recommended that high priority should be given to wider implementation of evidence-based initiatives to increase uptake of screening programmes, including breast and cervical screening programmes. The Department, NHS England and Public Health England are now considering the findings of Professor Richards’ report and will publish an implementation plan early next year.
In the interim, NHS England is investing in initiatives to help ensure equality of access to screening. These include locally-targeted interventions such as text and general practitioner (GP) reminder letters. As part of the delivery of the GP Five Year Forward View, the NHS has invested more than £258 million to improve access to general practice including improved access to all routine appointments (including screening) at weekends and/or evenings.
We are world leading in genomics and should celebrate that. A recent trial at Addenbrooke’s Hospital in Cambridge provided whole genome sequencing, identifying underlying genetic conditions for babies and children in intensive care. As a result, three quarters of those young patients received changes to their care. The NHS genomic service is working to embed genomics in routine healthcare. Later this year, the national genomic healthcare strategy will set out the ambitious programme for the next 10 years.
We are world leading in genomics and should celebrate that. A recent trial at Addenbrooke’s Hospital in Cambridge provided whole genome sequencing, identifying underlying genetic conditions for babies and children in intensive care. As a result, three quarters of those young patients received changes to their care. The NHS genomic service is working to embed genomics in routine healthcare. Later this year, the national genomic healthcare strategy will set out the ambitious programme for the next 10 years.
What recent assessment he has made of the merits of using genomics in healthcare.
With increasing direct-to-consumer genomic testing by private companies, can my hon. Friend advise what assessment has been made of the potential impact of self-referrals on NHS services?
With increasing direct-to-consumer genomic testing by private companies, can my hon. Friend advise what assessment has been made of the potential impact of self-referrals on NHS services?
Patients who need a genomic test from the national genomic test directory will be referred to the NHS genomic medicine service. However, I recognise
that some patients may contact their GP for advice after taking a commercial test. NHS England is working with partners to ensure that GPs receive training to help them respond correctly. Public Health England and the National Screening Committee have also published guidance on private screening.
Patients who need a genomic test from the national genomic test directory will be referred to the NHS genomic medicine service. However, I recognise
that some patients may contact their GP for advice after taking a commercial test. NHS England is working with partners to ensure that GPs receive training to help them respond correctly. Public Health England and the National Screening Committee have also published guidance on private screening.
Patients who need a genomic test from the national genomic test directory will be referred to the NHS genomic medicine service. However, I recognise
that some patients may contact their GP for advice after taking a commercial test. NHS England is working with partners to ensure that GPs receive training to help them respond correctly. Public Health England and the National Screening Committee have also published guidance on private screening.
With increasing direct-to-consumer genomic testing by private companies, can my hon. Friend advise what assessment has been made of the potential impact of self-referrals on NHS services?
Health service professionals in the Black Country are concerned that the removal of local funding for in-house molecular testing for cancer in April in favour of regional genomic laboratory hubs could in certain circumstances cause delays in diagnosis and be more expensive. Will the Minister look at this again in order to refine the processes to address these particular issues?
Health service professionals in the Black Country are concerned that the removal of local funding for in-house molecular testing for cancer in April in favour of regional genomic laboratory hubs could in certain circumstances cause delays in diagnosis and be more expensive. Will the Minister look at this again in order to refine the processes to address these particular issues?
Clinicians should be in charge of the process, and I have been assured that the change, using genomic testing, is better for patients and better for outcomes, but I would of course be happy to meet the hon. Gentleman and discuss it further.
Clinicians should be in charge of the process, and I have been assured that the change, using genomic testing, is better for patients and better for outcomes, but I would of course be happy to meet the hon. Gentleman and discuss it further.
Clinicians should be in charge of the process, and I have been assured that the change, using genomic testing, is better for patients and better for outcomes, but I would of course be happy to meet the hon. Gentleman and discuss it further.
Health service professionals in the Black Country are concerned that the removal of local funding for in-house molecular testing for cancer in April in favour of regional genomic laboratory hubs could in certain circumstances cause delays in diagnosis and be more expensive. Will the Minister look at this again in order to refine the processes to address these particular issues?
I commend the Minister for the progressive approach the Government have taken to genomics, but for a large number of genetic diseases the symptoms do not manifest themselves until after developmental damage has been done. Will the Government consider whether we should extend genomic testing to all neonates—all newborns—at some point in the future?
I commend the Minister for the progressive approach the Government have taken to genomics, but for a large number of genetic diseases the symptoms do not manifest themselves until after developmental damage has been done. Will the Government consider whether we should extend genomic testing to all neonates—all newborns—at some point in the future?
The Government are very open to such an approach. Genomics is transformative, and the early detection of disease means that we can treat patients from birth better and more efficiently.
The Government are very open to such an approach. Genomics is transformative, and the early detection of disease means that we can treat patients from birth better and more efficiently.
The Government are very open to such an approach. Genomics is transformative, and the early detection of disease means that we can treat patients from birth better and more efficiently.
I commend the Minister for the progressive approach the Government have taken to genomics, but for a large number of genetic diseases the symptoms do not manifest themselves until after developmental damage has been done. Will the Government consider whether we should extend genomic testing to all neonates—all newborns—at some point in the future?
Surely all this must be put in the context of the Topol review, with so much innovation and not just in genomics? There is so much innovation going on in the health service, but we have to make sure that there are well-managed and efficient hospital trusts running these programmes. Many are not like Huddersfield and are not up to speed, and we have to get hospitals up to speed in using the new technologies.
Surely all this must be put in the context of the Topol review, with so much innovation and not just in genomics? There is so much innovation going on in the health service, but we have to make sure that there are well-managed and efficient hospital trusts running these programmes. Many are not like Huddersfield and are not up to speed, and we have to get hospitals up to speed in using the new technologies.
I totally agree with the hon. Gentleman, and my constituency neighbour, the Secretary of State, is totally on this programme.
I totally agree with the hon. Gentleman, and my constituency neighbour, the Secretary of State, is totally on this programme.
I totally agree with the hon. Gentleman, and my constituency neighbour, the Secretary of State, is totally on this programme.
Surely all this must be put in the context of the Topol review, with so much innovation and not just in genomics? There is so much innovation going on in the health service, but we have to make sure that there are well-managed and efficient hospital trusts running these programmes. Many are not like Huddersfield and are not up to speed, and we have to get hospitals up to speed in using the new technologies.